摘要
目的 探讨左卡尼汀联合促红细胞生成素治疗肾性贫血的临床疗效。方法 选取本院2012年10月~2014年10月诊治的肾性贫血患者136例,采用随机数字表法分为两组,对照组68例采用促红细胞生成素治疗,观察组68例采用左卡尼汀联合促红细胞生成素治疗,比较两组临床指标改变、病症改善、临床疗效、不良反应情况。结果 治疗后,两组血红蛋白、红细胞压积、转铁蛋白饱和度、铁蛋白增加,差异具有统计学意义（P〈0.05）。观察组血红蛋白、红细胞压积、转铁蛋白饱和度、铁蛋白、病症（低血压、食欲减退、心律失常、肌痉挛）改善率、总有效率高于对照组,差异具有统计学意义（P〈0.05）。两组不良反应（肝肾功能异常、发热、胃肠道反应）比较,差异无统计学意义（P〉0.05）。结论 左卡尼汀联合促红细胞生成素治疗肾性贫血的疗效显著,临床指标及病症改善明显。
Objective To investigate clinical effect of levocarnitine and erythropoietin in treatment of renal anemia.Methods136 patients with renal anemia were selected in hospital from October 2012 to October 2014, who were divided into two groups by random number table method. 68 patients treated erythropoietin as control group. 68 patients treated levocarnitine and erythropoietin as observation group. Clinical index change, disease improvement, clinical effect, adverse reaction were compared between two groups.Results After treatment, hemoglobin, packcd cell volume, transferrin saturation, ferritin increased in two groups, the difference was statistically signiifcant （P〈0.05）. Hemoglobin, packcd cell volume, transferrin saturation, ferritin, diseases （low blood pressure, loss of appetite, arrhythmia, muscle spasm） improvement rate, total effective rate in observation group were higher than control group, the difference was statistically significant （P〈0.05）. Compared with adverse reactions （liver and kidney dysfunction, fever, gastrointestinal reactions） in two groups, difference was not statistically significant （P〉0.05）.Conclusion Levocarnitine and erythropoietin have signiifcant effect in treatment of renal anemia, which can signiifcantly improve clinical parameters and symptoms.
出处
《中国继续医学教育》
2016年第25期165-167,共3页
China Continuing Medical Education
